SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 316 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,993,000 | -29.3% | 50,000 | -44.4% | 1.30% | -6.8% |
| Q1 2017 | $2,817,000 | +11.6% | 90,000 | -10.0% | 1.39% | -7.7% |
| Q4 2016 | $2,525,000 | -66.0% | 100,000 | -66.7% | 1.51% | +14.1% |
| Q3 2016 | $7,420,000 | +61.9% | 300,000 | +33.3% | 1.32% | -29.0% |
| Q2 2016 | $4,583,000 | +9.3% | 225,000 | -18.2% | 1.86% | +21.3% |
| Q1 2016 | $4,194,000 | +108.0% | 275,000 | +83.3% | 1.54% | +131.8% |
| Q4 2015 | $2,016,000 | +6.4% | 150,000 | +11.1% | 0.66% | -11.0% |
| Q3 2015 | $1,894,000 | -57.9% | 135,000 | -49.1% | 0.74% | -47.5% |
| Q2 2015 | $4,500,000 | -25.6% | 265,000 | -47.0% | 1.42% | -44.2% |
| Q1 2015 | $6,045,000 | +45.7% | 500,000 | 0.0% | 2.54% | +26.8% |
| Q4 2014 | $4,150,000 | -20.4% | 500,000 | -16.7% | 2.01% | -28.0% |
| Q3 2014 | $5,215,000 | +27.0% | 600,000 | +60.0% | 2.79% | +45.4% |
| Q2 2014 | $4,107,000 | +359.4% | 375,000 | +275.0% | 1.92% | +363.9% |
| Q1 2014 | $894,000 | – | 100,000 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |